On August 6, Artivion Inc. (NYSE:AORT) reported second-quarter 2026 results that read as if two different companies wrote them. Revenue for the quarter ended June 30 climbed 11% on a GAAP basis to $125.8 million, and the company finished assembling what it calls the only complete aortic arch portfolio in its industry. Yet the same quarter produced a net loss of $13.5 million, a sharp reversal from a profit a year earlier. Investors drawn in by the growth story now have to reconcile it with a bottom line moving in the opposite direction.
A Complete Aortic Arch Arsenal
Revenue grew 9% on a non-GAAP constant currency basis in the second quarter of 2026 versus the second quarter of 2025, with On-X leading at 18% growth and stent grafts, including AMDS, up 12%. Adjusted EBITDA rose 7% to $26.4 million from $24.8 million a year earlier. Two milestones landed in the same quarter. Artivion completed its acquisition of Endospan Ltd., adding the NEXUS Aortic Arch Stent Graft System, and received US FDA approval of the PMA for its AMDS Hybrid Prosthesis. Together with its existing ARCEVO LSA device, the company says AMDS and NEXUS give it a three-pronged aortic arch lineup that no competitor can currently match globally.
NEXUS is also described as a platform supporting three additional PMA programs in development, which points to further products down the line. Management pointed to a return to growth across every international geography during the quarter, and reiterated its full-year 2026 revenue guidance of $480 million to $496 million. The ARTIZEN program is enrolling as expected, another sign the pipeline behind the current products is moving on schedule.
The Losses Keep Piling Up
The growth numbers sit next to a net loss of $13.5 million, or $0.28 per fully diluted share, compared to net income of $1.3 million, or $0.03 per share, in the second quarter of 2025. Non-GAAP net income also moved the wrong way, falling to $6.3 million, or $0.13 per share, from $10.7 million, or $0.24 per share, a year earlier. That non-GAAP figure absorbed a $0.7 million pretax loss tied to foreign currency revaluation. Despite closing the Endospan deal and winning FDA approval for AMDS, both flagged as key 2026 goals, Artivion reiterated its full-year guidance rather than raising it, and that guidance still bakes in roughly $8 million of Endospan-related expense for 2026.
The company is also carrying currency exposure from prior periods, having recorded a $2.3 million reserve in late 2025 tied to potential Italian government repayment rules on medical device spending. None of this erases the growth, but it shows the cost of building the acquisition and approval story is landing directly on profitability right now.
What The Smart Money Sees
The number of hedge funds holding Artivion fell to 24 from 28 the prior quarter, a pullback in institutional conviction even as revenue grew. Short interest sits at 7.21% of float, which points to a real but not overwhelming bear camp positioned against the stock. The forward P/E stands at 37.59, as of September 15, a multiple that assumes a meaningful earnings recovery from a company that just posted a GAAP loss. That combination suggests that the market hasn’t fully settled on which version of this quarter matters more.
Two Stories, One Stock
Artivion now owns a product portfolio few rivals can claim, with AMDS, NEXUS, and ARCEVO LSA covering the aortic arch and a pipeline of additional PMA programs behind them. It also just posted a widening net loss and a shrinking non-GAAP profit in the same quarter it hit those milestones. For the growth case to hold up, that portfolio needs to convert into earnings without the integration and currency costs eating the gains. For the skeptics, the reiterated rather than raised guidance is the tell that management isn’t yet ready to promise the payoff is close.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
